Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients

Introduction: Randomized trials demonstrated ~95% efficacy of SARS-CoV-2 spike messenger RNA (mRNA) vaccines. Patients (pts) after allogeneic hematopoietic cell transplant (HCT) have a variable period of immune deficiency and the impact of diagnosis, treatment regimens, GvHD, and immunosuppression o...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Melissa, Cortes, Maria, Ahn, Jaeil, Donato, Michele L., Kaur, Sukhdeep, Suh, Hyung C., Morawski, Alison, McKiernan, Phyllis, Einstein, Amy, Boonstra, Michele, Rowley, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
723.Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701534/
http://dx.doi.org/10.1182/blood-2021-145642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701534/
http://dx.doi.org/10.1182/blood-2021-145642

Ejemplares similares